0000899243-20-026691.txt : 20201001
0000899243-20-026691.hdr.sgml : 20201001
20201001175217
ACCESSION NUMBER: 0000899243-20-026691
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200929
FILED AS OF DATE: 20201001
DATE AS OF CHANGE: 20201001
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PDL BIOPHARMA, INC.
CENTRAL INDEX KEY: 0000882104
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39473
FILM NUMBER: 201217350
BUSINESS ADDRESS:
STREET 1: 932 SOUTHWOOD BLVD
CITY: INCLINE VILLAGE
STATE: NV
ZIP: 89451
BUSINESS PHONE: 775-832-8500
MAIL ADDRESS:
STREET 1: 932 SOUTHWOOD BLVD
CITY: INCLINE VILLAGE
STATE: NV
ZIP: 89451
FORMER NAME:
FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE
DATE OF NAME CHANGE: 19930328
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LENSAR, Inc.
CENTRAL INDEX KEY: 0001320350
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 320125724
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2800 DISCOVERY DRIVE
STREET 2: SUITE 100
CITY: ORLANDO
STATE: FL
ZIP: 32826
BUSINESS PHONE: 888-536-7271
MAIL ADDRESS:
STREET 1: 2800 DISCOVERY DRIVE
STREET 2: SUITE 100
CITY: ORLANDO
STATE: FL
ZIP: 32826
FORMER COMPANY:
FORMER CONFORMED NAME: LensAR Inc
DATE OF NAME CHANGE: 20070703
FORMER COMPANY:
FORMER CONFORMED NAME: LaserSoft Vision Inc
DATE OF NAME CHANGE: 20050310
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-29
1
0001320350
LENSAR, Inc.
LNSR
0000882104
PDL BIOPHARMA, INC.
932 SOUTHWOOD BOULEVARD
INCLINE VILLAGE
NV
89451
0
0
1
0
Common Stock
2020-09-29
4
P
0
8703
11.16
A
8667397
D
Common Stock
2020-10-01
4
J
0
8667397
0.00
D
0
D
In connection with the separation of the Issuer from the Reporting Person on October 1, 2020, the Reporting Person distributed all of the shares of common stock of the Issuer in the form of a dividend to its stockholders.
/s/ Edward Imbrogno, Chief Financial Officer of PDL BioPharma, Inc.
2020-10-01